TrialEye (London, England)2024

ROBIN: a randomised, double-masked, placebo-controlled Phase IIa study of the AOC3 inhibitor BI 1467335 in diabetic retinopathy.

Quan Dong Nguyen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.